Innovative Therapeutic Approach for Viral Diseases and Cancer Treatment

Introduction

Treating viral diseases and proliferative disorders like cancer remains one of the most significant challenges in modern medicine. While existing therapies can be effective, they often face limitations such as resistance, side effects, or inefficiencies in targeting abnormal cell growth. Our patented method offers a groundbreaking approach to treating these conditions by modulating biological pathways to combat both viral infections and uncontrolled cell proliferation, opening new possibilities for more effective and targeted treatments. This technology is poised to become a key tool for pharmaceutical companies looking to expand their therapeutic portfolios in the areas of virology and oncology.

The Complexities of Treating Viral Diseases and Proliferative Disorders

In the fight against viral diseases, traditional treatments like antiviral drugs can struggle with resistance as viruses mutate and evade therapeutic interventions. Moreover, the treatment of proliferative disorders, such as cancers, is often complicated by the difficulty in targeting abnormal cells without harming healthy tissues. This makes it imperative for new therapies to provide a more specific mechanism of action, with reduced side effects and improved patient outcomes.

For pharmaceutical companies, there is a growing need for innovative therapies that can both address viral infections and inhibit the proliferation of abnormal cells. Developing such treatments requires a deep understanding of the underlying mechanisms that drive these conditions, enabling more effective intervention at the molecular level.

A Dual-Action Approach to Treatment

Our patented method offers a unique, dual-action therapeutic approach by targeting the pathways involved in both viral replication and cellular proliferation. By modulating specific biological mechanisms, this method interrupts the processes that allow viruses to replicate within the body and simultaneously inhibits the abnormal growth of cells in proliferative disorders like cancer. This dual focus offers a powerful and versatile tool for treating a wide range of conditions, from viral infections like hepatitis and HIV to cancers of various origins.

This method is particularly valuable because it can be applied to develop treatments that are both more targeted and less likely to result in resistance. By focusing on fundamental biological processes shared by both viral diseases and proliferative disorders, this technology provides a broad platform for therapeutic development, allowing pharmaceutical companies to create drugs that can address multiple conditions with a single mechanism of action.

Key Benefits

Dual Therapeutic Focus: Targets both viral infections and abnormal cell proliferation, offering broad therapeutic applications.
Reduced Risk of Resistance: Provides a more specific mechanism of action, reducing the likelihood of drug resistance in viral diseases.
Broad Applications: Suitable for treating various viral diseases and cancers, offering a versatile platform for pharmaceutical development.
Improved Patient Outcomes: Offers a targeted approach that reduces side effects and improves efficacy compared to traditional treatments.

A Promising Platform for Future Therapies

Licensing this method for treating viral diseases and proliferative disorders gives pharmaceutical and biotechnology companies a valuable tool for expanding their research and development pipelines. With its dual-action mechanism and broad applicability, this technology opens new doors for creating highly effective treatments that address some of the most pressing challenges in modern medicine.

Please see terms and conditions

Abstract
Claims

Lobster hemolymph and compositions derived therefrom for the prevention or treatment of viral diseases or cancer by systemic administration.

What is claimed is:

1. A method of treating a proliferative disorder in a mammal afflicted therewith, said method comprising internally administering an effective amount of lobster hemolymph, lobster hemocyanin, or a derivative of lobster hemocyanin.

2. The method of claim 1, wherein the method comprises internally administering lobster hemocyanin purified or partially purified from lobster hemolymph or a derivative of such lobster hemocyanin.

3. The method of claim 1, wherein the method comprises internally administering a derivative of lobster hemocyanin that is selected from fragmented lobster hemocyanin, an active fraction of lobster hemocyanin or of fragmented hemocyanin, or a glycosylated form of lobster hemocyanin, an active fraction of lobster hemocyanin, or of fragmented lobster hemocyanin.

4. The method of claim 3, wherein the derivative of lobster hemocyanin is a glycosylated form of lobster hemocyanin or of fragmented lobster hemocyanin.

5. The method of claim 4, wherein the derivative of lobster hemocyanin is a glycosylated form of lobster hemocyanin or of fragmented lobster hemocyanin prepared by admixing the hemocyanin or fragmented hemocyanin with an aqueous sugar solution.

6. The method of claim 5, wherein the aqueous sugar solution is diluted honey.

7. The method of claim 3, wherein the derivative of lobster hemocyanin is a glycosylated form of lobster hemocyanin.

8. The method of claim 1, wherein the hemocyanin preparation is proteolyzed lobster hemocyanins prepared by admixing and reacting a protease with lobster hemocyanins for a time and under conditions such that the hemocyanins are proteolyzed.

9. The method of claim 1, wherein the lobster is Homarus americanus, Homarus gammarus, or Panulirus argus.

10. The method of claim 1, wherein the hemocyanin or derivative thereof is administered in a pharmaceutical composition comprising one or more sugars.

11. The method of claim 10 wherein the composition comprises honey.

12. The method of claim 1, wherein the lobster hemocyanin or derivative thereof is administered orally, transdermally, transmucosolly, or parenterally.

13. The method of claim 12, wherein the lobster hemocyanin or derivative thereof is administered orally or parenterally.

14. The method of claim 1, wherein the proliferative disorder is a cancer selected from a group consisting of solid tumors, carcinomas, sarcomas, Kaposi’s sarcoma, erythroblastoma, glioblastoma, meningioma, astrocytoma, melanoma and myoblastoma, and leukemia.

15. The method of claim 14, wherein the method comprises co-administering a cancer antigen.

16. The method of claim 15, wherein the antigen is admixed with the lobster hemocyanin.

17. The method of claim 16, wherein the antigen is conjugated to the lobster hemocyanin.

18. A method of stimulating an immune response to an antigen in a mammal, said method comprising co-administering to the mammal the antigen and an adjuvant selected from lobster hemocyanin, fragmented lobster hemocyanin, an active fraction of lobster hemocyanin or of fragmented hemocyanin, or a glycosylated form of lobster hemocyanin, an active fraction of lobster hemocyanin, or of fragmented lobster hemocyanin.

19. The method of claim 18 wherein the antigen is conjugated to the lobster hemocyanin.

20. A method of treating a viral infection in a mammal afflicted therewith, said method comprising internally administering an effective amount of a lobster hemolymph, lobster hemocyanin, or a derivative of lobster hemocyanin.

21. The method of claim 20, wherein the mammal is treated for a viral infection selected from the group consisting of ebola viruses, Herpes Simplex Virus 1 (HSV-1), HSV-2, Herpes Zoster (VZV), Equine Herpesvirus-1, Feline Herpesvirus-1, Epstein-Barr virus, Human Immune Deficiency virus, Cytomegalovirus, human papilloma virus, rhinovirus, and influenza virus.

22. The method of claim 21, wherein the viral infection is an HSV infection.

23. The method of claim 22, wherein the viral infection is an HSV-1 infection.

24. The method of claim 20, wherein the derivative of lobster hemocyanin is selected from fragmented lobster hemocyanin, an active fraction of lobster hemocyanin or of fragmented hemocyanin, or a glycosylated form of lobster hemocyanin or of fragmented lobster hemocyanin.

25. The method of claim 24, wherein the hemocyanin preparation is proteolyzed lobster hemocyanins prepared by admixing and reacting a protease with lobster hemocyanins for a time and under conditions such that the hemocyanins are proteolyzed.

26. The method of claim 20, wherein the lobster hemocyanin or derivative thereof is administered orally, transdermally, transmucosolly, or parenterally.

27. The method of claim 20, wherein the lobster hemocyanin or derivative thereof is administered orally or parenterally.

28. The method of claim 20, wherein the lobster is Homarus americanus, Homarus gammarus, or Panulirus argus.

29. The method of claim 20, wherein the hemocyanin or derivative thereof is administered in a pharmaceutical composition comprising one or more sugars.

30. The method of claim 29, wherein the composition comprises honey.

Title

Method of treating viral diseases and proliferative disorders

Inventor(s)

Robert C. Bayer

Assignee(s)

Lobster Unlimited LLC

Patent #

10456427

Patent Date

October 29, 2019